GLENMARK.BO

Glenmark Pharmaceuticals Limited

$2,349.05

+13.45 (+0.58%)

Mkt Cap 659.11B

Volume 7,289

52W Range 1372-2471.05

Sector Healthcare

Beta 0.31

EPS (TTM) 37.74

P/E Ratio 61.89

Revenue (TTM) 164.08B

Rev Growth (5Y) +4.6%

EPS Growth (5Y) +6.2%

Company Description

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.

Track Record

Showing latest 4 periods • Swipe for more

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	133.63B	126.45B	116.56B	123.05B	109.44B	106.57B	98.65B	90.74B	90.79B	75.73B	65.56B	59.45B
Net Income	10.47B	(15.02B)	2.97B	9.42B	9.70B	7.76B	9.25B	8.04B	9.16B	7.02B	4.75B	5.42B
EPS	37.11	-67.30	-6.01	33.37	34.38	27.50	32.78	28.49	32.46	25.01	17.52	20.01
Free Cash Flow	(15.77B)	(11.64B)	176.29M	3.19B	3.56B	4.61B	870.00M	6.03B	(910.97M)	(5.45B)	N/A	N/A
FCF / Share	-55.89	-41.25	0.62	11.29	12.63	16.34	3.08	21.38	-3.23	-19.42	N/A	N/A
Operating CF	(8.28B)	(2.65B)	6.25B	11.09B	11.31B	13.92B	13.24B	16.48B	6.57B	3.45B	N/A	N/A
Total Assets	160.50B	143.59B	193.72B	170.83B	156.04B	146.85B	132.96B	130.21B	122.12B	108.36B	N/A	N/A
Total Debt	24.73B	12.31B	46.08B	39.62B	49.86B	51.86B	44.49B	46.39B	47.24B	39.88B	N/A	N/A
Cash & Equiv	17.05B	16.58B	11.59B	14.11B	11.38B	11.10B	9.36B	12.33B	10.56B	8.57B	N/A	N/A
Book Value	88.49B	78.48B	94.74B	90.87B	70.65B	60.71B	56.05B	55.89B	49.39B	42.70B	N/A	N/A
Return on Equity	0.12	-0.19	0.03	0.10	0.14	0.13	0.17	0.14	0.19	0.16	N/A	N/A

Metric	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023
Revenue	39.01B	60.47B	32.64B	31.96B	34.19B	34.34B	32.44B	38.95B	25.07B	32.07B	34.02B	30.01B
Net Income	4.03B	6.10B	468.71M	46.50M	3.48B	3.54B	3.40B	(12.18B)	(3.51B)	(819.45M)	1.50B	(4.28B)
EPS	14.29	21.63	1.66	0.16	12.33	12.55	12.06	-44.03	-16.66	-7.10	5.31	-31.72
Free Cash Flow	N/A	23.35B	0	0	0	0	0	0	2.94B	2.83B	3.09B	67.74M
FCF / Share	N/A	82.76	N/A	N/A	N/A	N/A	N/A	N/A	10.42	10.03	10.95	0.24
Operating CF	N/A	28.36B	0	0	0	0	0	0	2.94B	2.83B	3.09B	67.74M
Total Assets	N/A	190.02B	0	160.50B	0	152.35B	0	143.59B	0	200.06B	0	193.72B
Total Debt	N/A	12.24B	0	24.73B	0	17.81B	0	12.31B	0	51.82B	0	46.08B
Cash & Equiv	N/A	26.47B	0	17.05B	0	18.19B	16.59B	16.58B	(11.24B)	11.23B	(14.70B)	11.59B
Book Value	N/A	95.82B	88.49B	88.49B	84.45B	84.46B	78.48B	78.48B	97.36B	93.27B	98.39B	94.74B
Return on Equity	N/A	0.06	0.01	0.00	0.04	0.04	0.04	-0.16	-0.04	-0.01	0.02	-0.05

GLENMARK.BO News

No news available for GLENMARK.BO.